Cisplatin, etoposide and continuous infusion bleomycin in patients with testicular germ cell tumors: Efficacy and toxicity data from a retrospective study

Giuseppe Curigliano, G. Spitaleri, E. Magni, K. Lorizzo, O. De Cobelli, M. Locatelli, L. Fumagalli, L. Adamoli, M. Cossu Rocca, E. Verri, T. De Pas, E. Jereczek-Fossa, G. Martinelli, A. Goldhksch, F. Nolè

Research output: Contribution to journalArticle

Abstract

We retrospectively reviewed medical charts of 54 patients who underwent orchidectomy for germ cell tumors (GCT) and received a regimen, given every 3 weeks, consisting of cisplatin 100 mg/m2 day 4 intravenous (i.v.), bleomycin 15 Units (U) day 1 i.v. push; bleomycin 10 U days 1-3 24 h i.v. continuous infusion (c.i.) and etoposide 100 mg/m2 days 1-5/i.v. (PEB). 53 of 54 patients achieved a complete remission without adjunctive surgery. At a median follow-up of 48.2 months (95%CI 41.7 - 54.8 months) all patients but one are alive with no evidence of disease recurrence. Patients receiving PEB experienced no pulmonary toxicity, nephrotoxicity nor neurological adverse events. PEB with c.i. bleomycin is an active regimen with a low rate of acute and late toxicity. The main limitations of our study are related to the retrospective analysis, the limited number of patients and the restricted follow-up time. A prolonged follow-up is necessary to evaluate long term toxicity and outcome.

Original languageEnglish
Pages (from-to)687-692
Number of pages6
JournalJournal of Chemotherapy
Volume21
Issue number6
Publication statusPublished - Dec 2009

Fingerprint

Etoposide
Cisplatin
Retrospective Studies
Bleomycin
Orchiectomy
Germ Cell and Embryonal Neoplasms
Intravenous Infusions
indium-bleomycin
Testicular Germ Cell Tumor
Recurrence
Lung

Keywords

  • Bleomycin
  • Cisplatin
  • Etoposide
  • Germ cells testicular cancer

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Infectious Diseases
  • Oncology
  • Pharmacology
  • Medicine(all)

Cite this

Cisplatin, etoposide and continuous infusion bleomycin in patients with testicular germ cell tumors : Efficacy and toxicity data from a retrospective study. / Curigliano, Giuseppe; Spitaleri, G.; Magni, E.; Lorizzo, K.; De Cobelli, O.; Locatelli, M.; Fumagalli, L.; Adamoli, L.; Cossu Rocca, M.; Verri, E.; De Pas, T.; Jereczek-Fossa, E.; Martinelli, G.; Goldhksch, A.; Nolè, F.

In: Journal of Chemotherapy, Vol. 21, No. 6, 12.2009, p. 687-692.

Research output: Contribution to journalArticle

@article{f81937de16e1483d87b96854effe5b41,
title = "Cisplatin, etoposide and continuous infusion bleomycin in patients with testicular germ cell tumors: Efficacy and toxicity data from a retrospective study",
abstract = "We retrospectively reviewed medical charts of 54 patients who underwent orchidectomy for germ cell tumors (GCT) and received a regimen, given every 3 weeks, consisting of cisplatin 100 mg/m2 day 4 intravenous (i.v.), bleomycin 15 Units (U) day 1 i.v. push; bleomycin 10 U days 1-3 24 h i.v. continuous infusion (c.i.) and etoposide 100 mg/m2 days 1-5/i.v. (PEB). 53 of 54 patients achieved a complete remission without adjunctive surgery. At a median follow-up of 48.2 months (95{\%}CI 41.7 - 54.8 months) all patients but one are alive with no evidence of disease recurrence. Patients receiving PEB experienced no pulmonary toxicity, nephrotoxicity nor neurological adverse events. PEB with c.i. bleomycin is an active regimen with a low rate of acute and late toxicity. The main limitations of our study are related to the retrospective analysis, the limited number of patients and the restricted follow-up time. A prolonged follow-up is necessary to evaluate long term toxicity and outcome.",
keywords = "Bleomycin, Cisplatin, Etoposide, Germ cells testicular cancer",
author = "Giuseppe Curigliano and G. Spitaleri and E. Magni and K. Lorizzo and {De Cobelli}, O. and M. Locatelli and L. Fumagalli and L. Adamoli and {Cossu Rocca}, M. and E. Verri and {De Pas}, T. and E. Jereczek-Fossa and G. Martinelli and A. Goldhksch and F. Nol{\`e}",
year = "2009",
month = "12",
language = "English",
volume = "21",
pages = "687--692",
journal = "Journal of Chemotherapy",
issn = "1120-009X",
publisher = "Maney Publishing",
number = "6",

}

TY - JOUR

T1 - Cisplatin, etoposide and continuous infusion bleomycin in patients with testicular germ cell tumors

T2 - Efficacy and toxicity data from a retrospective study

AU - Curigliano, Giuseppe

AU - Spitaleri, G.

AU - Magni, E.

AU - Lorizzo, K.

AU - De Cobelli, O.

AU - Locatelli, M.

AU - Fumagalli, L.

AU - Adamoli, L.

AU - Cossu Rocca, M.

AU - Verri, E.

AU - De Pas, T.

AU - Jereczek-Fossa, E.

AU - Martinelli, G.

AU - Goldhksch, A.

AU - Nolè, F.

PY - 2009/12

Y1 - 2009/12

N2 - We retrospectively reviewed medical charts of 54 patients who underwent orchidectomy for germ cell tumors (GCT) and received a regimen, given every 3 weeks, consisting of cisplatin 100 mg/m2 day 4 intravenous (i.v.), bleomycin 15 Units (U) day 1 i.v. push; bleomycin 10 U days 1-3 24 h i.v. continuous infusion (c.i.) and etoposide 100 mg/m2 days 1-5/i.v. (PEB). 53 of 54 patients achieved a complete remission without adjunctive surgery. At a median follow-up of 48.2 months (95%CI 41.7 - 54.8 months) all patients but one are alive with no evidence of disease recurrence. Patients receiving PEB experienced no pulmonary toxicity, nephrotoxicity nor neurological adverse events. PEB with c.i. bleomycin is an active regimen with a low rate of acute and late toxicity. The main limitations of our study are related to the retrospective analysis, the limited number of patients and the restricted follow-up time. A prolonged follow-up is necessary to evaluate long term toxicity and outcome.

AB - We retrospectively reviewed medical charts of 54 patients who underwent orchidectomy for germ cell tumors (GCT) and received a regimen, given every 3 weeks, consisting of cisplatin 100 mg/m2 day 4 intravenous (i.v.), bleomycin 15 Units (U) day 1 i.v. push; bleomycin 10 U days 1-3 24 h i.v. continuous infusion (c.i.) and etoposide 100 mg/m2 days 1-5/i.v. (PEB). 53 of 54 patients achieved a complete remission without adjunctive surgery. At a median follow-up of 48.2 months (95%CI 41.7 - 54.8 months) all patients but one are alive with no evidence of disease recurrence. Patients receiving PEB experienced no pulmonary toxicity, nephrotoxicity nor neurological adverse events. PEB with c.i. bleomycin is an active regimen with a low rate of acute and late toxicity. The main limitations of our study are related to the retrospective analysis, the limited number of patients and the restricted follow-up time. A prolonged follow-up is necessary to evaluate long term toxicity and outcome.

KW - Bleomycin

KW - Cisplatin

KW - Etoposide

KW - Germ cells testicular cancer

UR - http://www.scopus.com/inward/record.url?scp=77649293465&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77649293465&partnerID=8YFLogxK

M3 - Article

C2 - 20071294

AN - SCOPUS:77649293465

VL - 21

SP - 687

EP - 692

JO - Journal of Chemotherapy

JF - Journal of Chemotherapy

SN - 1120-009X

IS - 6

ER -